H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on DiaMedica Therapeutics (DMAC) to $10 from $7 and keeps a Buy rating on the shares. The firm believes the greatest near-term catalyst for the recombinant human tissue kallikrein-1 vascular disease pipeline is the preliminary Phase 2 investigator-sponsored safety and efficacy topline anticipated in Q2 for pregnancy complication preeclampsia. The firm is optimistic going into the dataset for DiaMedica’s lead candidate DM199.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DMAC:
- DiaMedica Therapeutics Reports 2024 Financial Results
- DiaMedica Therapeutics’ Optimistic Earnings Call Highlights
- DiaMedica Therapeutics Reports 2024 Financial Results and Strategic Advancements
- DiaMedica Therapeutics reports FY24 EPS (60c), consensus (59c)
- DMAC Earnings this Week: How Will it Perform?
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue